Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Gene Voss who wrote (4318)	1/5/1998 11:02:00 AM
From: LoLoLoLita	Read Replies (1) \| Respond to of 23519

>>Regarding systemic damage from oral meds. Gene-- You have excellent comments. What I'd like some of the M.D.s to address are these questions: what constitutes "safety" for an ED therapy, and, is there a "lower bar" used by FDA etc. in assessing drugs for (IMHO) non-life-threatening illnesses? It seems logical to suppose that the "acceptable" level of bad reactions for ED therapies should be substantially less than what is considered OK for drugs used for chemotherapy, organ transplants, heart attacks, etc. I believe that recent recalls of a "diet pill" and an antihistamine are evidence that this may be the case. Will this affect the future of Viagra? My professional background is that of a risk analyst working on issues related to nuclear accidents. We constantly struggle with the question of "acceptable risk." I'd greatly appreciate any cites to journal articles or books on how this question is addressed in the drug approval/monitoring process. David P.S. According to Yahoo, VVUS has picked up a few new analysts, albeit with HOLDs; there are seven now. quote.yahoo.com